Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized phase 3 study of two adagrasib dose regimens in previously treated KRAS G12C-mutated non-small cell lung cancer
MOH_2024-05-16_013407Phase 3Not yet recruiting
- Sponsor
- Mirati Therapeutics
- Start
- May 2024
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of adagrasib in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Mirati Therapeutics. Planned start May 2024; status: not yet recruiting.
02
Drugs
adagrasib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on MOH_2024-05-16_013407.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2024-05-16_013407.